BDX up +1.40% percent right now. $BDX High is at 1
Post# of 46498
Posted On: 11/10/2014 1:16:13 PM
BDX up +1.40% percent right now. $BDX High is at 127.49 and the Low 125.58 with current volume of 378,298.
Recent News posted below.
BDX Becton Dickinson and Company Recent Headline News
SmarTrend Watching for Potential Rebound in Shares of Becton Dickinson After 1.87% Loss
Comtex SmarTrend(R) - Fri Nov 07, 4:07PM CST
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $125.35 to a high of $128.20. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $125.94 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 127.32 (+1.78)
Becton Dickinson Falls 1.87% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Nov 07, 4:07PM CST
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $125.35 to a high of $128.20. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $125.94 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 127.32 (+1.78)
CareFusion Q1 Earnings, Revenues Rise and Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:30AM CST
CareFusion Corporation (CFN) now expects adjusted earnings to increase in the range of $2.80-$2.95 per share, higher than the earlier band of $2.60-$2.75 per share.
BDX: 127.32 (+1.78), BCR: 162.87 (+0.49), BAX: 70.55 (-0.06), CFN: 57.34 (+0.06)
Techne on an Acquisition Spree, Buys CyVek for $60M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:41PM CST
Techne Corp. (TECH) intends to leverage CyPlex, CyVek's breakthrough technology to derive maximum value from its extensive reagents portfolio.
GE: 26.49 (+0.08), BDX: 127.32 (+1.78), TMO: 116.96 (+0.36), TECH: 90.52 (-0.19)
Becton Dickinson (BDX) Earnings Report: Q4 2014 Conference Call Transcript
at The Street - Tue Nov 04, 11:41AM CST
The following Becton Dickinson (BDX) conference call took place on November 4, 2014, 08:00 AM ET. This is a transcript of that earnings call:
BDX: 127.32 (+1.78)
Becton, Dickinson (BDX) Beats Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:03AM CST
Becton, Dickinson and Company (BDX) reported fourth-quarter fiscal 2014 earnings of $1.68 per share, which beat the Zacks Consensus Estimate by 3 cents.
BDX: 127.32 (+1.78), FLDM: 28.89 (-0.01), BEAT: 8.08 (-0.07), ANGO: 16.90 (-0.05)
Becton Dickinson (BDX) Showing Signs Of Being Water-Logged And Getting Wetter
at The Street - Tue Nov 04, 9:59AM CST
Trade-Ideas LLC identified Becton Dickinson (BDX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
BDX: 127.32 (+1.78)
Becton, Dickinson (BDX) Stock Rises Today After Fourth Quarter Earnings Beat
at The Street - Tue Nov 04, 8:46AM CST
Becton, Dickinson (BDX) shares are climbing after the company beat analysts fourth quarter earnings expectations.
BDX: 127.32 (+1.78)
BD Announces Results For 2014 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2015 Guidance
PR Newswire - Tue Nov 04, 5:00AM CST
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.202 billion for the fourth fiscal quarter ended September 30, 2014, representing an increase of 4.8 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis. For the full fiscal year ended September 30, 2014, BD reported revenues of $8.446 billion, representing an increase of 4.9 percent over the prior-year period, or 5.2 percent on a foreign currency-neutral basis.
BDX: 127.32 (+1.78)
Will Becton, Dickinson (BDX) Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:53PM CDT
Becton, Dickinson and Company (BDX) is set to report fourth-quarter fiscal 2014 results on Nov 4.
BDX: 127.32 (+1.78), ALNY: 98.78 (+2.94), PTN: 0.78 (+0.03), HSIC: 129.37 (+0.53)
Luminex Tops Q3 Earnings, Revenues in Line; Outlook Weak - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:40PM CDT
Luminex Corporation's (LMNX) earnings per share jumped sharply to 22 cents from a penny in the year-ago quarter driven by strong revenue growth and margin expansion.
BDX: 127.32 (+1.78), LMNX: 18.17 (+0.13), AFFX: 9.37 (-0.06), HOLX: 26.40 (+0.19)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of CareFusion Corporation of Class Action Against the Board of Directors of the Company Challenging the Fairness of the Sale of the Company to Becton Dickinson & Co. -- CFN
GlobeNewswire - Mon Oct 20, 9:28AM CDT
Levi & Korsinsky notifies investors of CareFusion Corporation ("CareFusion" or "the Company"
(NYSE:CFN) of claims of breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Becton Dickinson & Co. ("Becton Dickinson" . A complaint was filed in Delaware state court.
BDX: 127.32 (+1.78), CFN: 57.34 (+0.06)
CAREFUSION CORPORATION ALERT - Andrews & Springer LLC is Seeking More Cash for Shareholders of CareFusion Corporation
GlobeNewswire - Mon Oct 20, 8:38AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of CareFusion Corporation ("CareFusion" or the "Company" relating to the sale of the Company to Becton Dickinson & Company ("Becton" . On October 5, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which Becton will acquire CareFusion in a merger worth $12.2 billion. As a result of the merger, CareFusion shareholders are only anticipated to receive a total of $58.00 per share ($49.00 per share in cash and 0.0777 of a share of Becton) in exchange for each share of CareFusion.
BDX: 127.32 (+1.78), CFN: 57.34 (+0.06)
Earnings Releases, Conference Call Schedule, Acquisitions, Drug Launches, and Initiation of Study - Research Reports on KeyCorp, Itau Unibanco, BD, Mylan and GlaxoSmithKline
PR Newswire - Mon Oct 20, 8:20AM CDT
Today, Analysts Review released its research reports regarding KeyCorp. (NYSE: KEY), Itau Unibanco Holding S.A. (NYSE: ITUB), Becton, Dickinson and Company (NYSE: BDX), Mylan Inc. (NASDAQ: MYL) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7300-100free.
BDX: 127.32 (+1.78), MYL: 53.77 (+0.66), GSK: 45.17 (+0.26), KEY: 13.43 (+0.04), ITUB: 14.21 (+0.11)
SmarTrend Watching for Potential Rebound in Shares of Becton Dickinson After 3.01% Loss
Comtex SmarTrend(R) - Thu Oct 16, 4:15PM CDT
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $120.29 to a high of $123.64. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $121.11 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 127.32 (+1.78)
Watch for Becton Dickinson to Potentially Rebound After Falling 3.01% Yesterday
Comtex SmarTrend(R) - Thu Oct 16, 4:15PM CDT
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $120.29 to a high of $123.64. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $121.11 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 127.32 (+1.78)
Becton, Dickinson Acquires GenCell Biosystems in Ireland - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 12:10PM CDT
The GenCell acquisition will enable Becton, Dickinson and Company (BDX) to offer a differentiated platform in the NGS market, constructing a base to further expand its genomics offerings.
BDX: 127.32 (+1.78), CAH: 78.74 (+0.47), CFN: 57.34 (+0.06), COO: 164.56 (-0.44)
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of CareFusion Corporation Concerning the Fairness of the Sale of the Company to Becton Dickinson & Co. -- CFN
Business Wire - Tue Oct 14, 8:55AM CDT
Levi & Korsinsky is investigating the Board of Directors of CareFusion Corporation ("CareFusion" or "the Company" (NYSE:CFN) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Becton Dickinson & Co. ("Becton Dickinson" .
BDX: 127.32 (+1.78), CFN: 57.34 (+0.06)
BD Acquires GenCell Biosystems
PR Newswire - Mon Oct 13, 7:00AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired GenCell Biosystems, a privately-held Irish biotech company that has developed proprietary technologies that address key biological analysis protocols - from library preparation of Next Generation Sequencing (NGS) to genotyping for agricultural applications.
BDX: 127.32 (+1.78)
CAREFUSION CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of CareFusion Corp. (CFN) Over the Proposed Sale of the Company to Becton, Dickinson & Co.
Business Wire - Fri Oct 10, 6:15PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of CareFusion Corp. ("CareFusion" or the "Company" (NYSE:CFN) for potential breaches of fiduciary duties in connection with the sale of the Company to Becton, Dickinson & Co. ("Becton Dickinson" (NYSE: BDX) in a cash and stock deal valued at approximately $12.2 billion. The Company's stockholders will receive $49 in cash and .0777 shares of Becton Dickinson for a total consideration of $58 per share of CareFusion common stock they own. The deal price is subject to change based on Becton Dickinson's stock price.
BDX: 127.32 (+1.78), CFN: 57.34 (+0.06)
Recent News posted below.
BDX Becton Dickinson and Company Recent Headline News
SmarTrend Watching for Potential Rebound in Shares of Becton Dickinson After 1.87% Loss
Comtex SmarTrend(R) - Fri Nov 07, 4:07PM CST
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $125.35 to a high of $128.20. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $125.94 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 127.32 (+1.78)
Becton Dickinson Falls 1.87% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Nov 07, 4:07PM CST
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $125.35 to a high of $128.20. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $125.94 on volume of 1.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 127.32 (+1.78)
CareFusion Q1 Earnings, Revenues Rise and Beat Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:30AM CST
CareFusion Corporation (CFN) now expects adjusted earnings to increase in the range of $2.80-$2.95 per share, higher than the earlier band of $2.60-$2.75 per share.
BDX: 127.32 (+1.78), BCR: 162.87 (+0.49), BAX: 70.55 (-0.06), CFN: 57.34 (+0.06)
Techne on an Acquisition Spree, Buys CyVek for $60M - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 5:41PM CST
Techne Corp. (TECH) intends to leverage CyPlex, CyVek's breakthrough technology to derive maximum value from its extensive reagents portfolio.
GE: 26.49 (+0.08), BDX: 127.32 (+1.78), TMO: 116.96 (+0.36), TECH: 90.52 (-0.19)
Becton Dickinson (BDX) Earnings Report: Q4 2014 Conference Call Transcript
at The Street - Tue Nov 04, 11:41AM CST
The following Becton Dickinson (BDX) conference call took place on November 4, 2014, 08:00 AM ET. This is a transcript of that earnings call:
BDX: 127.32 (+1.78)
Becton, Dickinson (BDX) Beats Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 11:03AM CST
Becton, Dickinson and Company (BDX) reported fourth-quarter fiscal 2014 earnings of $1.68 per share, which beat the Zacks Consensus Estimate by 3 cents.
BDX: 127.32 (+1.78), FLDM: 28.89 (-0.01), BEAT: 8.08 (-0.07), ANGO: 16.90 (-0.05)
Becton Dickinson (BDX) Showing Signs Of Being Water-Logged And Getting Wetter
at The Street - Tue Nov 04, 9:59AM CST
Trade-Ideas LLC identified Becton Dickinson (BDX) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
BDX: 127.32 (+1.78)
Becton, Dickinson (BDX) Stock Rises Today After Fourth Quarter Earnings Beat
at The Street - Tue Nov 04, 8:46AM CST
Becton, Dickinson (BDX) shares are climbing after the company beat analysts fourth quarter earnings expectations.
BDX: 127.32 (+1.78)
BD Announces Results For 2014 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2015 Guidance
PR Newswire - Tue Nov 04, 5:00AM CST
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.202 billion for the fourth fiscal quarter ended September 30, 2014, representing an increase of 4.8 percent from the prior-year period, or 4.6 percent on a foreign currency-neutral basis. For the full fiscal year ended September 30, 2014, BD reported revenues of $8.446 billion, representing an increase of 4.9 percent over the prior-year period, or 5.2 percent on a foreign currency-neutral basis.
BDX: 127.32 (+1.78)
Will Becton, Dickinson (BDX) Beat Q4 Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 3:53PM CDT
Becton, Dickinson and Company (BDX) is set to report fourth-quarter fiscal 2014 results on Nov 4.
BDX: 127.32 (+1.78), ALNY: 98.78 (+2.94), PTN: 0.78 (+0.03), HSIC: 129.37 (+0.53)
Luminex Tops Q3 Earnings, Revenues in Line; Outlook Weak - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 12:40PM CDT
Luminex Corporation's (LMNX) earnings per share jumped sharply to 22 cents from a penny in the year-ago quarter driven by strong revenue growth and margin expansion.
BDX: 127.32 (+1.78), LMNX: 18.17 (+0.13), AFFX: 9.37 (-0.06), HOLX: 26.40 (+0.19)
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of CareFusion Corporation of Class Action Against the Board of Directors of the Company Challenging the Fairness of the Sale of the Company to Becton Dickinson & Co. -- CFN
GlobeNewswire - Mon Oct 20, 9:28AM CDT
Levi & Korsinsky notifies investors of CareFusion Corporation ("CareFusion" or "the Company"
(NYSE:CFN) of claims of breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Becton Dickinson & Co. ("Becton Dickinson" . A complaint was filed in Delaware state court. BDX: 127.32 (+1.78), CFN: 57.34 (+0.06)
CAREFUSION CORPORATION ALERT - Andrews & Springer LLC is Seeking More Cash for Shareholders of CareFusion Corporation
GlobeNewswire - Mon Oct 20, 8:38AM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of CareFusion Corporation ("CareFusion" or the "Company"
relating to the sale of the Company to Becton Dickinson & Company ("Becton" . On October 5, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which Becton will acquire CareFusion in a merger worth $12.2 billion. As a result of the merger, CareFusion shareholders are only anticipated to receive a total of $58.00 per share ($49.00 per share in cash and 0.0777 of a share of Becton) in exchange for each share of CareFusion. BDX: 127.32 (+1.78), CFN: 57.34 (+0.06)
Earnings Releases, Conference Call Schedule, Acquisitions, Drug Launches, and Initiation of Study - Research Reports on KeyCorp, Itau Unibanco, BD, Mylan and GlaxoSmithKline
PR Newswire - Mon Oct 20, 8:20AM CDT
Today, Analysts Review released its research reports regarding KeyCorp. (NYSE: KEY), Itau Unibanco Holding S.A. (NYSE: ITUB), Becton, Dickinson and Company (NYSE: BDX), Mylan Inc. (NASDAQ: MYL) and GlaxoSmithKline plc (NYSE: GSK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7300-100free.
BDX: 127.32 (+1.78), MYL: 53.77 (+0.66), GSK: 45.17 (+0.26), KEY: 13.43 (+0.04), ITUB: 14.21 (+0.11)
SmarTrend Watching for Potential Rebound in Shares of Becton Dickinson After 3.01% Loss
Comtex SmarTrend(R) - Thu Oct 16, 4:15PM CDT
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $120.29 to a high of $123.64. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $121.11 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 127.32 (+1.78)
Watch for Becton Dickinson to Potentially Rebound After Falling 3.01% Yesterday
Comtex SmarTrend(R) - Thu Oct 16, 4:15PM CDT
Becton Dickinson (NYSE:BDX) traded in a range yesterday that spanned from a low of $120.29 to a high of $123.64. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $121.11 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BDX: 127.32 (+1.78)
Becton, Dickinson Acquires GenCell Biosystems in Ireland - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 14, 12:10PM CDT
The GenCell acquisition will enable Becton, Dickinson and Company (BDX) to offer a differentiated platform in the NGS market, constructing a base to further expand its genomics offerings.
BDX: 127.32 (+1.78), CAH: 78.74 (+0.47), CFN: 57.34 (+0.06), COO: 164.56 (-0.44)
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of CareFusion Corporation Concerning the Fairness of the Sale of the Company to Becton Dickinson & Co. -- CFN
Business Wire - Tue Oct 14, 8:55AM CDT
Levi & Korsinsky is investigating the Board of Directors of CareFusion Corporation ("CareFusion" or "the Company"
(NYSE:CFN) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Becton Dickinson & Co. ("Becton Dickinson" . BDX: 127.32 (+1.78), CFN: 57.34 (+0.06)
BD Acquires GenCell Biosystems
PR Newswire - Mon Oct 13, 7:00AM CDT
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired GenCell Biosystems, a privately-held Irish biotech company that has developed proprietary technologies that address key biological analysis protocols - from library preparation of Next Generation Sequencing (NGS) to genotyping for agricultural applications.
BDX: 127.32 (+1.78)
CAREFUSION CORP. INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of CareFusion Corp. (CFN) Over the Proposed Sale of the Company to Becton, Dickinson & Co.
Business Wire - Fri Oct 10, 6:15PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of CareFusion Corp. ("CareFusion" or the "Company"
(NYSE:CFN) for potential breaches of fiduciary duties in connection with the sale of the Company to Becton, Dickinson & Co. ("Becton Dickinson" (NYSE: BDX) in a cash and stock deal valued at approximately $12.2 billion. The Company's stockholders will receive $49 in cash and .0777 shares of Becton Dickinson for a total consideration of $58 per share of CareFusion common stock they own. The deal price is subject to change based on Becton Dickinson's stock price. BDX: 127.32 (+1.78), CFN: 57.34 (+0.06)
(0)
(0)Scroll down for more posts ▼